In this study, we conducted a large‐scale prospective study using the Fudan breast cancer‐specific NGS panel, summarising the correlation between clinical and genomic variation in RTK‐PI3K‐MAPK pathways, and illustrated the adaptive roles of PIK3CA mutations in HER2+ tumour progression. This evidence concerns the gene PIK3CA and breast carcinoma.